# Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

Source: https://onco.cc/trials/nct07619521/  
OnCo record `nct07619521` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of selumetinib and trastuzumab deruxtecan in pancreatic cancer, run by National Cancer Institute (NCI), now recruiting.

## Summary

Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma is a phase 1/2, interventional study registered as NCT07619521 by National Cancer Institute (NCI), with a registry enrolment figure of 31 participants, started 2027-06-01 and due to reach its primary completion in 2028-09-08. Interventions recorded: Biospecimen Collection; Diagnostic Imaging Testing; Echocardiography Test; Multigated Acquisition Scan; Selumetinib; Trastuzumab Deruxtecan. Conditions listed: Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma. Primary outcome: Occurrence of dose limiting toxicities (DLTs) (dose escalation phase); HER2 expression status (dose escalation phase); Overall response rate (phase II). Pancreatic eligibility wording from the registry: "* Patients must have histologically or cytologically confirmed adenocarcinoma of the pancreas". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07619521
- Phase: 1/2
- Setting: Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT07619521: https://clinicaltrials.gov/study/NCT07619521

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Selumetinib](https://onco.cc/drugs/selumetinib/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07619521.json